Results 31 to 40 of about 3,663 (172)

Alirocumab in the management of primary hypercholesterolaemia or mixed dyslipidaemia: A budget impact analysis – Italian perspective

Global & Regional Health Technology Assessment, 2018
Recent evidence suggests that adding protein convertase subtilisin/kexin type 9 inhibitors to current lipid-lowering therapies may result in unprecedented reductions in low-density lipoprotein cholesterol.
Alessia Marocco, Sanja Stanisic, Francesca Fanelli, Francesco Damele, Furio Colivicchi   +4 more
doaj   +1 more source

Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography

Lipids in Health and Disease, 2021
Background Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors have been demonstrated to produce significantly greater reduction in LDL cholesterol levels and cardiovascular events than standard statin therapy.
Fei Gao, Zhi Jian Wang, Xiao Teng Ma, Hua Shen, Li Xia Yang, Yu Jie Zhou   +5 more
doaj   +1 more source

Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis

Critical Care Explorations, 2023
OBJECTIVES:. Treatments that prevent sepsis complications are needed. Circulating lipid and protein assemblies—lipoproteins play critical roles in clearing pathogens from the bloodstream.
Patrick R. Lawler, MD, MPH, Garen Manvelian, PhD, Alida Coppi, PhD, Amy Damask, PhD, Michael N. Cantor, MD, Manuel A. R. Ferreira, PhD, Charles Paulding, PhD, Nilanjana Banerjee, PhD, Dadong Li, PhD, Susan Jorgensen, MS, Richa Attre, PhD, David J. Carey, PhD, Kristi Krebs, PhD, Lili Milani, PhD, Kristian Hveem, MD, Jan K. Damås, PhD, Erik Solligård, PhD, Stefan Stender, MD, Anne Tybjærg-Hansen, MD, Børge G. Nordestgaard, MD, Tamara Hernandez-Beeftink, PhD, Tormod Rogne, MD, Carlos Flores, PhD, Jesús Villar, MD, Keith R. Walley, MD, Vincent X. Liu, MD, Alison E. Fohner, PhD, Luca A. Lotta, MD, Christos A. Kyratsous, PhD, Mark W. Sleeman, PhD, Michel Scemama, MD, Richard DelGizzi, MS, Robert Pordy, MD, Julie E. Horowitz, PhD, Aris Baras, MD, Greg S. Martin, MD, Philippe Gabriel Steg, MD, Gregory G. Schwartz, MD, Michael Szarek, PhD, Shaun G. Goodman, MD   +39 more
doaj   +1 more source

A 32‐Year‐Old Man With an Cardiomyopathy

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Scleredema is a sclerosing dermatosis of unknown etiology, characterized by non‐punctate, weakly infiltrated skin thickening and swelling, which can lead to the development of cardiomyopathy. Scleredema‐associated cardiomyopathy is at present poorly understood.
Yuting Zou, Shan Li, Tong Chen, Yi Li
wiley   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1547-1554, June 2026.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source

PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice

Drugs - Real World Outcomes, 2019
Background Several lipid guidelines recommend that proprotein convertase subtilisin/kexin type 9 inhibitors should be considered for patients with atherosclerotic cardiovascular disease who are inadequately treated with maximally tolerated lipid-lowering
Klaus G. Parhofer, Berndt von Stritzky, Nicole Pietschmann, Cornelia Dorn, W. Dieter Paar   +4 more
doaj   +1 more source

Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study

Atherosclerosis Plus, 2021
Background and aims: The benefits of the PCSK9 inhibitors, alirocumab and evolocumab, in lowering LDL-cholesterol and preventing major adverse cardiac events (MACE) have been demonstrated in pivotal clinical trials.
Marina Blanco-Ruiz, Laura Amaya-Pascasio, Reyes de Torres Chacón, María Josefa Álvarez Soria, Antonio Arjona-Padillo, María Magdalena Carrillo Bailén, Rodrigo Milán Pinilla, Irene Pérez Ortega, Belén Sánchez Rodríguez, Luis Andrade Zumárraga, Roberto Valverde Moyano, Manuel Payán Ortiz, Alba María Castillo Fernández, Cristina Del Toro Pérez, Pablo González Bustos, Eduardo Agüera Morales, Purificación Sánchez López, Beatriz Hidalgo Martín, Ricardo Roa Chamorro, Javier Fernández Pérez, María Victoria Mejías Olmedo, Patricia Martínez-Sánchez   +21 more
doaj   +1 more source

Impact of CYP2C19 Genotype Variants on PCSK9 Inhibitor Efficacy in Lipid‐Lowering Among Patients With Symptomatic Intracranial Atherosclerotic Stenosis

Lipids, Volume 61, Issue 3, Page 319-329, May 2026.
ABSTRACT Ischemic stroke is frequently associated with symptomatic intracranial atherosclerotic stenosis (sICAS), is a leading cause of global disability and mortality. Current guidelines recommend dual antiplatelet and intensive statin therapies. Proprotein convertase subtilisin 9/kexin type 9 (PCSK9) inhibitors have emerged as a potent lipid‐lowering
Chao Zhao, Nuan Wang, Di Shi, Hao Zhou, Dan Chen, Guofang Chen   +5 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale

Lipids in Health and Disease, 2017
Background Statins are generally well-tolerated and serious side effects are infrequent, but some patients experience adverse events and reduce their statin dose or discontinue treatment altogether. Alirocumab is a highly specific, fully human monoclonal
Tamio Teramoto, Akira Kondo, Arihiro Kiyosue, Mariko Harada-Shiba, Yasushi Ishigaki, Kimimasa Tobita, Yumiko Kawabata, Asuka Ozaki, Marie T. Baccara-Dinet, Masataka Sata   +9 more
doaj   +1 more source